Compare Fubotv Inc (FUBO) vs Natera Inc. Common Stock (NTRA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Fubotv Inc vs Natera Inc. Common Stock — how do they compare? Fubotv Inc trades at $8.22 (market cap $894.32M), while Natera Inc. Common Stock trades at $394 (market cap $57.03B). The key difference: Natera Inc. Common Stock is far larger — about 63.8× Fubotv Inc's market cap, and Natera Inc. Common Stock is trading nearer its 52-week high, Fubotv Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Fubotv Inc for 35 Days and Natera Inc. Common Stock for 0 Days on average.
| FUBO | NTRA | |
|---|---|---|
Market Cap | $894.32M | $57.03B |
Volume | 1,279,134 | 1,131,157 |
Sector | Media | Health |
52-Week High | $48.96 | $425.64 |
52-Week Low | $8.09 | $179.42 |
Typical Hold Time | 35 Days | 0 Days |
Enterprise Value | $1.07B | $56.18B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
FUBO trades at $8.26, down 5.49% on the day, reflecting a bearish technical trend. The stock shows deep undervaluation with a P/E of 2.13 and P/S of 0.16, but fundamentals are mixed with a net loss of $172.25M in 2024 despite revenue growth to $1.62B. Recent news highlights strategic partnerships, including NHL streaming deals and the launch of My Local Sports, aiming to boost subscriber growth and advertising revenue.
The outlook remains speculative; a projected net profit of $123M in 2025 suggests a potential turnaround, but persistent cash burn and high debt levels pose significant risks. Analyst consensus is divided with a $63.38 price target, indicating substantial upside if execution improves, yet the bearish technical signals and competitive pressures warrant caution for investors.
NTRA trades at $395.66, down 0.53% today but remains near recent highs. The stock shows mixed technical signals with neutral momentum indicators. Fundamentally, the company demonstrates strong revenue growth ($2.31B in 2025, projected $2.7B in 2026) but continues to operate at a net loss (-$208M in 2025). Recent positive developments include FDA Breakthrough Device designation for its multi-cancer detection assay and regulatory approval in Japan for Signatera.
NTRA presents a growth story with significant analyst support (89% buy ratings) but carries execution risks. The stock trades at premium valuations (P/S 20.48) while still unprofitable. Key catalysts include clinical trial progress and international expansion, though investors face risks from ongoing losses and competitive pressures in precision medicine.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Fubotv Inc
FuboTV Inc is a sports-first, live TV streaming company, offering subscribers access to tens of thousands of live sporting events annually as well as news and entertainment content. Its platform, fuboTV, allows customers to access content through streaming devices and on SmartTVs, mobile phones, tablets, and computers. The company offer subscribers a live TV streaming service with the option to purchase incremental features available for purchase that include additional content or enhanced functionality best suited to their preferences. The operating segments of the group are Streaming and Online wagering, of which a majority of revenue is derived from the Streaming segment. It has a business presence in the U.S. and other international countries.
Read more on FUBO →About Natera Inc. Common Stock
Natera, Inc. develops and provides cell-free DNA-based genetic testing across women's health, oncology, organ health, and rare disease, with flagship products including Panorama for noninvasive prenatal screening and Signatera for cancer recurrence monitoring.
Read more on NTRA →
